4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reaffirmed at Weiss Ratings
Weiss Ratings reaffirmed their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report report published on Saturday morning,Weiss Ratings reports. FDMT has been the topic of several other research reports. Chardan Capital restated a “buy” rating and set a $39.00 target price on shares of 4D Molecular […]
More Stories
Wall Street Slides on Opening Bell as Oil Surges Past $100 Amid Iran War Jitters
By Tom Ozimek Wall Street’s main indexes opened in the red on March 9 as investors reacted to a surge...
Is Untamed Season 2 Released? Know about the Release Date and Cast
Netflix’s American crime drama television series, Untamed, got a lot of praise after its debut in 2025. It topped the...
Saudi Arabia Warns Iran It Will Be ‘The Greatest Loser’ If It Escalates Attacks
By Jack Phillips Saudi Arabia issued a fresh warning to Iran on Monday following an Iranian attack that killed two...
USPS Could Run Out of Funds in 1 Year Without Congressional Action: Postmaster General
By Kimberly Hayek U.S. Postal Service Postmaster General David Steiner said on March 4 that the service could run out...
MobLand Season 2: Release Date, Cast, Trailer, and Expected Plot
Since the debut of the crime drama MobLand, it has become one of the most talked-about 10-episode series. With its...
100 Percent of Audited Medicaid Claims for Autism Care in Colorado Were Improper or Flawed: Report
By Sylvia Xu Colorado’s Medicaid program made an estimated $77.8 million in improper payments and another $207.4 million in potentially...